PMID- 21184843 OWN - NLM STAT- MEDLINE DCOM- 20110329 LR - 20211020 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1811 IP - 3 DP - 2011 Mar TI - Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate's efficacy against bipolar disorder. PG - 163-9 LID - 10.1016/j.bbalip.2010.12.006 [doi] AB - BACKGROUND: The ability of chronic valproate (VPA) to reduce arachidonic acid (AA) turnover in brain phospholipids of unanesthetized rats has been ascribed to its inhibition of acyl-CoA synthetase (Acsl)-mediated activation of AA to AA-CoA. Our aim was to identify a rat Acsl isoenzyme that could be inhibited by VPA in vitro. METHODS: Rat Acsl3-, Acsl6v1- and Acsl6v2-, and Acsl4-flag proteins were expressed in E. coli, and the ability of VPA to inhibit their activation of long-chain fatty acids to acyl-CoA was estimated using Michaelis-Menten kinetics. RESULTS: VPA uncompetitively inhibited Acsl4-mediated conversion of AA and of docosahexaenoic (DHA) but not of palmitic acid to acyl-CoA, but did not affect AA conversion by Acsl3, Acsl6v1 or Acsl6v2. Acsl4-mediated conversion of AA to AA-CoA showed substrate inhibition and had a 10-times higher catalytic efficiency than did conversion of DHA to DHA-CoA. Butyrate, octanoate, or lithium did not inhibit AA activation by Acsl4. CONCLUSIONS: VPA's ability to inhibit Acsl4 activation of AA and of DHA to their respective acyl-CoAs, when related to the higher catalytic efficiency of AA than DHA conversion, may account for VPA's selective reduction of AA turnover in rat brain phospholipids, and contribute to VPA's efficacy against bipolar disorder. CI - Copyright (c) 2010 Elsevier B.V. All rights reserved. FAU - Shimshoni, Jakob A AU - Shimshoni JA AD - National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. FAU - Basselin, Mireille AU - Basselin M FAU - Li, Lei O AU - Li LO FAU - Coleman, Rosalind A AU - Coleman RA FAU - Rapoport, Stanley I AU - Rapoport SI FAU - Modi, Hiren R AU - Modi HR LA - eng GR - P30 ES010126/ES/NIEHS NIH HHS/United States GR - R01 DK059935/DK/NIDDK NIH HHS/United States GR - ZIA AG000145-09/ImNIH/Intramural NIH HHS/United States GR - DK59935/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20101222 PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Anticonvulsants) RN - 0 (Arachidonic Acids) RN - 0 (Isoenzymes) RN - 0 (Nerve Tissue Proteins) RN - 0 (Recombinant Proteins) RN - 25167-62-8 (Docosahexaenoic Acids) RN - 27YG812J1I (Arachidonic Acid) RN - 614OI1Z5WI (Valproic Acid) RN - EC 6.2.1.- (Acsl4 protein, rat) RN - EC 6.2.1.- (Coenzyme A Ligases) SB - IM MH - Acylation/drug effects MH - Animals MH - Anticonvulsants/*chemistry/pharmacology MH - Arachidonic Acid/chemistry/metabolism MH - Arachidonic Acids/chemistry/metabolism MH - Bipolar Disorder/drug therapy/*enzymology MH - Brain/*enzymology MH - Coenzyme A Ligases/*chemistry/genetics/metabolism MH - Docosahexaenoic Acids/chemistry/metabolism MH - Enzyme Activation/drug effects MH - Escherichia coli MH - Humans MH - Isoenzymes/chemistry/metabolism MH - Nerve Tissue Proteins/*chemistry/metabolism MH - Rats MH - Recombinant Proteins/chemistry/metabolism MH - Valproic Acid/*chemistry/pharmacology PMC - PMC3037030 MID - NIHMS266619 COIS- Disclosure/Conflict of interest. No author has a financial or other conflict of interest related to this work. EDAT- 2010/12/28 06:00 MHDA- 2011/03/30 06:00 PMCR- 2012/03/01 CRDT- 2010/12/28 06:00 PHST- 2010/08/19 00:00 [received] PHST- 2010/12/10 00:00 [revised] PHST- 2010/12/15 00:00 [accepted] PHST- 2010/12/28 06:00 [entrez] PHST- 2010/12/28 06:00 [pubmed] PHST- 2011/03/30 06:00 [medline] PHST- 2012/03/01 00:00 [pmc-release] AID - S1388-1981(10)00254-4 [pii] AID - 10.1016/j.bbalip.2010.12.006 [doi] PST - ppublish SO - Biochim Biophys Acta. 2011 Mar;1811(3):163-9. doi: 10.1016/j.bbalip.2010.12.006. Epub 2010 Dec 22.